06.05.26 -- Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane

Whole health looks beyond traditional care by addressing food access, environment, and lived experiences—leading to healthier communities and more holistic outcomes.

Bridge the enrollment gap by blending site-based tactics with global direct-to-patient outreach. Use digital screening and EMR intelligence to ensure faster, more predictable paths to randomization.

Explore key themes surrounding payments to clinical research participants in depth, with a particular focus on the role of participant compensation and best practices in payment logistics.

What triggers trial rescue? Poor planning, complex protocols, missed deadlines, limited resources, and noncompliance. Addressing these early helps sponsors prevent delays and avoid rescue mode.

By following this checklist, research teams can enhance organizational efficiency, maintain compliance with regulatory standards, and confidently navigate the complexities of documentation management.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

Discover how this patented synthetic approach to Deucravacitinib intermediates can improve yield, simplify purification, and support scalable, regulatory-aligned manufacturing.